Travere Therapeutics officer proposes $101K sale
The reported sale is tied to tax withholding on vested performance restricted stock units and is described as required rather than discretionary.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jula Inrig, an officer of Travere Therapeutics, Inc. (TVTX), reported a proposed sale of 2,174 common shares, with an aggregate market value of $101,417.10 and an approximate sale date of May 5, 2026. The shares were acquired through vesting of performance restricted stock units on May 4, 2026. The remarks state that the sale is required to fund tax withholding under the issuer’s equity incentive plans and is not a discretionary trade.
Key Figures
Key Terms
Performance Restricted Stock Unit Vesting financial
sell to cover financial
tax withholding obligation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.